David Altshuler - 15 Nov 2021 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
15 Nov 2021
Net transactions value
-$6,365
Form type
4
Filing time
16 Nov 2021, 15:04:13 UTC
Previous filing
19 May 2021
Next filing
03 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $2,615 -14 -0.04% $186.80 33,609 15 Nov 2021 Direct F1, F2, F3
transaction VRTX Common Stock Sale $3,750 -20 -0.06% $187.51 33,589 15 Nov 2021 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $186.80 (range $186.22 to $187.19).
F3 Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $187.51 (range $187.26 to $187.79).